特罗凯的相关说明

我家特罗凯11天了，今天脸上不长小脓包了是怎么回事 耐药了吗？之前印易7个月 凡德1个月 阿西1个月都有效稳定，现在特中，求解？

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC
http://www.medwirenews.com/379/1 ... advanced_NSCLC.html
$ F) v2 A$ n: u2 Y* ~* jmedwireNews: Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown.
- H0 J( i+ ^% w9 w
+ p) P$ ?# ~0 m! M4 t9 l5 yThe trial also confirmed earlier suggestions that the development of a skin rash is associated with improved survival and that a “dosing to rash” strategy is clinically feasible.

The Eastern Cooperative Oncology Group Study enrolled an unselected cohort of 137 patients with untreated stage IIIB/IV NSCLC. They were treated with erlotinib starting at 150 mg once a day and the dose was escalated by 25 mg every 2 weeks up to 250 mg, unless a grade 2 rash or other dose-limiting toxicity occurred.

Patients who developed a tolerable grade 2 skin rash were maintained on the current dose and no further attempt was made at dose escalation; conversely, if any side effects became intolerable, the dose was reduced in 25 mg increments.
  a. A7 S! a2 V; o8 B3 i# t- ~* i; V
; O$ s! j+ X1 o( G9 O% S: [A total of 124 patients completed therapy and were included in the final analysis.
6 z( q+ ]- \! O3 W8 s' l3 U
1 e8 l7 u* \$ u8 tWriting in the European Journal of Cancer, Julie Brahmer (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA) and colleagues report that erlotinib was well tolerated in the first-line setting, with only 24.2% of patients discontinuing treatment due to toxicity and 8.1% refusing treatment.

Two (1%) patients died from treatment-related adverse events (pneumonitis and pulmonary infiltrates). The most common grade 1/2 adverse event was rash, affecting 70% of patients, while the most common grade 3 events were rash, fatigue, and diarrhea, each in 10% of patients.

/ P7 U/ ~& @5 t7 R5 ^$ _3 H) V2 y“Even with dose escalation to a grade 2 rash, not all patients developed a rash,” remark Brahmer et al.

In terms of efficacy, patient response rates and survival were consistent with those seen in other clinical trials of erlotinib. In all, 6.5% of patients had an objective response, 1.6% had a complete response, and 34.7% had stable disease, giving a disease control rate of 41.1%.

The median time to progression was 3.3 months and median overall survival was 7.7 months.

* L* ~/ J- k: e, M1 Z. l1 QInterestingly, patients who developed a grade 2 or greater rash did not have a better response rate or disease control rate than those who did not; however, these patients had significantly better overall survival, living for 6.8 months longer on average than patients without a rash.
8 q8 V! y! l9 U/ O
* S% n) U. J) A4 p1 |The researchers say their results indicate that erlotinib used as first-line treatment in an unselected population has similar efficacy to that of first-line chemotherapy. Furthermore, “intrapatient dose escalation of erlotinib beyond 150 mg to develop a tolerable rash was feasible.”

病人吞不下，是否可以咬碎吞下，或者泡水给他喝？

请教：靶向药有抑制新生血管的作用，我家有颈椎病，血液循环不好，抑制新生血管会不会导致加重？

请问大家，我妈肝癌肺转吃特罗凯3天了，发现肺部一按就有疼痛感，伸胳膊也有这种感觉，这是怎么回事，是特罗凯的副作用吗？

沙漠仙人掌 发表于 2014-2-15 08:58
- P; T  Y- n% D' D" J  q请问大家，我妈肝癌肺转吃特罗凯3天了，发现肺部一按就有疼痛感，伸胳膊也有这种感觉，这是怎么回事，是特 ...

特罗凯好像没这一副作用

回115楼, 正常血液循环不依赖新生血管.

我母亲吃特一个月，反复的口腔溃疡，还有脸上也干燥到脱皮.

请教老马，服用特罗凯三天，有个奇怪现象。白天一切都好，晚上睡觉后就腹胀，感觉肿瘤顶住胃，心慌恶心，十分难受，整夜难眠。医生检查腹部说有很多气体。伴有血压升高，医生开了心痛定，可短期降低，妈妈以前无高血压史。求助有碰到这种现象的吗？特罗凯有这种副作用吗？如何缓解？停药后症状消失，可不可以减量吃？比如100mg？现在是150mg的药丸，可以弄碎了吃吗？详细病情见帖子http://www.yuaigongwu.com/thread-13285-1-1.html，非常感谢！

请问大家，我妈服用13天特罗开，脸上出现大面积的干燥，红肿，非常严重，眼睛上眼皮也中起日来，擦拉VB6和百多邦反而红肿的面积更大，今天左边的头部和耳朵都有跟发烧样的情况，这是过敏吗，请问怎么样能够缓解这些皮肤症状，看着妈妈好痛苦！